{"id":"W2344298048","doi":"10.1016/j.jval.2015.03.974","title":"Canadian Public Reimbursement of Subsequent Entry Biologics (Sebs) / Biosimilars","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"","keywords":"Infliximab; Biosimilar; Reimbursement; Formulary; Medicine; Family medicine; Health care; Internal medicine; Disease; Political science","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005096353,0.0008022151,0.0007187079,0.00423996,0.003952786,0.005565991,0.002444105,0.004488821,0.03427911],"category_scores_gemma":[0.03223632,0.0006520678,0.002035865,0.00317439,0.00200309,0.0007860025,0.001652911,0.004388362,0.002358124],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.1237883,"about_ca_system_score_gemma":0.2740151,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9654118,"about_ca_topic_score_gemma":0.9671407,"domain_scores_codex":[0.9827094,0.001168138,0.0004017367,0.0006855384,0.0115912,0.003443977],"domain_scores_gemma":[0.9681559,0.003101739,0.001222574,0.0006748341,0.02005444,0.006790543],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001004107,0.0002029435,0.01337276,0.0005133542,0.0002208587,0.0006370447,0.0003341881,0.00135789,0.001695369,0.06082654,0.8055824,0.1142525],"study_design_scores_gemma":[0.0005541752,0.0002517085,0.05127739,0.0005691848,0.0002245501,0.0007765391,0.0005018351,0.00252644,0.001469015,0.002118166,0.9396121,0.0001188771],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"empirical","genre_scores_codex":[0.09117538,0.02126897,0.004546601,0.2982226,0.01095494,0.0009342735,0.02066123,0.002129551,0.5501063],"genre_scores_gemma":[0.687279,0.01414671,0.006878927,0.06060767,0.00274223,0.0001950981,0.01116057,0.0004648878,0.2165249],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.8762117,"threshold_uncertainty_score":0.8981513,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1314074851867528,"score_gpt":0.3296436078192548,"score_spread":0.198236122632502,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}